- ISIN
- US05464T1043
- CUSIP
- 05464T104
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Nov 19, 2015
Highlights
- Market Cap
- $12.69B
- Enterprise Value
- $12.67B
- EPS (TTM)
- -$3.74
- Total Revenue (TTM)
- $708.24M
- Gross Profit (TTM)
- $655.82M
- EBITDA (TTM)
- -$172.72M
- Year Range
- $96.09 - $260.19
- Target Price
- $243.13
- ROA (TTM)
- -26.39%
- ROE (TTM)
- -344.96%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
AXSM Performance Chart
Axsome Therapeutics, Inc. (AXSM) is up 35.7% since the beginning of the year. At $248 per share, AXSM is trading 4.7% below its 52-week high of $260. Investors who bought $1,000 worth of AXSM shares 5 years ago would now be looking at an investment worth $3,557.
Loading charts...
Returns By Period
Axsome Therapeutics, Inc. (AXSM) has returned 35.70% so far this year and 146.15% over the past 12 months. Looking at the last ten years, AXSM has achieved an annualized return of 42.66%, outperforming the S&P 500 Index benchmark, which averaged 13.88% per year.
Axsome Therapeutics, Inc.
- 1D
- -1.06%
- 1M
- 5.03%
- YTD
- 35.70%
- 6M
- 60.21%
- 1Y
- 146.15%
- 3Y*
- 41.16%
- 5Y*
- 28.89%
- 10Y*
- 42.66%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
AXSM Monthly Returns History
Based on dividend-adjusted daily data since Nov 19, 2015, AXSM's average daily return is +0.27%, while the average monthly return is +5.81%. At this rate, an investment would double in approximately 1.0 years.
Historically, 52% of months were positive and 48% were negative. The best month was Jan 2019 with a return of +197.5%, while the worst month was Jan 2018 at -50.0%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 5 months.
On a daily basis, AXSM closed higher 48% of trading days. The best single day was Jan 7, 2019 with a return of +161.2%, while the worst single day was Aug 9, 2021 at -46.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.88% | -11.05% | 3.13% | 22.91% | 12.87% | 5.70% | 35.70% | ||||||
| 2025 | 25.82% | 19.80% | -8.55% | -3.72% | -6.35% | -0.73% | -2.88% | 19.63% | 0.14% | 11.15% | 12.23% | 20.55% | 115.86% |
| 2024 | 13.12% | -9.61% | -1.94% | -7.57% | -0.45% | 9.63% | 8.46% | 1.78% | 1.14% | -0.93% | 10.32% | -13.86% | 6.31% |
| 2023 | -2.76% | -9.08% | -9.55% | 15.97% | 3.15% | -2.60% | 9.20% | 2.97% | -13.50% | -10.89% | 8.30% | 18.00% | 3.19% |
| 2022 | -27.37% | 2.44% | 47.24% | -23.29% | -21.26% | 53.20% | 0.76% | 65.33% | -30.06% | 1.19% | 60.11% | 6.70% | 104.16% |
| 2021 | -16.42% | -1.07% | -15.94% | 6.78% | 0.41% | 11.12% | -27.97% | -47.15% | 28.35% | 16.81% | -10.29% | 9.38% | -53.63% |
Benchmark Metrics
Axsome Therapeutics, Inc. has an annualized alpha of 70.84%, beta of 0.97, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since November 19, 2015.
- This stock captured 185.84% of S&P 500 Index gains but only 86.90% of its losses - a favorable profile for investors.
- R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 70.84%
- Beta
- 0.97
- R²
- 0.04
- Upside Capture
- 185.84%
- Downside Capture
- 86.90%
Return for Risk
Risk / Return Rank
AXSM ranks 97 for risk / return — in the top 97% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Axsome Therapeutics, Inc. (AXSM) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| AXSM | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.50 | ||
| Sortino ratioReturn per unit of downside risk | +2.15 | ||
| Omega ratioGain probability vs. loss probability | 1.59 | 1.37 | +0.23 |
| Calmar ratioReturn relative to maximum drawdown | 7.95 | 2.78 | +5.16 |
| Martin ratioReturn relative to average drawdown | 23.42 | 12.44 | +10.98 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Axsome Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Axsome Therapeutics, Inc. was 86.65%, occurring on Dec 27, 2018. Recovery took 59 trading sessions.
The current Axsome Therapeutics, Inc. drawdown is 2.87%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Rate-hike selloffLate 2018 | -86.65%Dec 2018 | 2y 11mo | 2mo 28d | 3y 2moJan 2016 - Mar 2019 |
2021 bear market2021 | -81.26%Aug 2021 | 1y 7mo | 3y 5mo | 5y 1moDec 2019 - Jan 2025 |
2019 bear market2019 | -42.70%Oct 2019 | 14d | 1mo 19d | 2mo 3dSep 2019 - Nov 2019 |
2025 selloff2025 | -30.56%Apr 2025 | 1mo 15d | 7mo | 8mo 15dFeb 2025 - Nov 2025 |
2026 correction2026 | -18.50%Mar 2026 | 1mo 19d | 1mo 19d | 3mo 8dJan 2026 - Apr 2026 |
Drawdown Indicators
| AXSM | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -86.65% | -56.78% | -29.87% |
Max Drawdown (1Y)Largest decline over 1 year | -18.50% | -9.10% | -9.40% |
Max Drawdown (3Y)Largest decline over 3 years | -34.83% | -18.90% | -15.93% |
Max Drawdown (5Y)Largest decline over 5 years | -72.91% | -25.43% | -47.48% |
Max Drawdown (10Y)Largest decline over 10 years | -81.26% | -33.92% | -47.34% |
Current DrawdownCurrent decline from peak | -2.87% | -1.80% | -1.07% |
Average DrawdownAverage peak-to-trough decline | -39.40% | -10.71% | -28.69% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 6.27% | 2.03% | +4.24% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Axsome Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Axsome Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for AXSM relative to other companies in the Biotechnology industry. Currently, AXSM has a P/S ratio of 17.6. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for AXSM in comparison with other companies in the Biotechnology industry. Currently, AXSM has a P/B value of 232.5. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with AXSM
Add Axsome Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with AXSM